Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE)
Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease
Sponsor: UNICANCER
Listed as NCT04158362, this PHASE3 trial focuses on Cancer Metastatic and remains ongoing. Sponsored by UNICANCER, it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 8 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jun 2022 — Feb 2024 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jun 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Suspended → Recruiting
-
May 2020 — Jul 2020 [monthly]
Suspended PHASE3
Status: Not Yet Recruiting → Suspended
-
Jan 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .